問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
National Taiwan University Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
下載
2021-01-01 - 2021-12-31
Condition/Disease
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy(CADASIL)
Test Drug
13N-NH3
Participate Sites1Sites
Recruiting1Sites
2019-12-20 - 2024-08-16
advanced hepatocellular carcinoma (HCC)
1. Regorafenib (BAY-73-4506) 2. Tislelizumab (BGB-A317)
Participate Sites2Sites
Recruiting2Sites
2020-06-11 - 2022-11-02
2020-08-01 - 2022-12-21
Vascular Cognitive Impairment/Alzheimer Disease
11C-PiB
Terminated1Sites
2020-08-01 - 2025-07-31
Cerebral Amyloid Angiopathy(CAA)
(1)11C-PiB (2)18F-T807
2018-07-01 - 2035-06-30
2018-03-18 - 2024-10-31
2018-07-01 - 2021-08-20
2018-09-01 - 2019-06-30
2018-08-01 - 2023-07-31
post-stroke
18F-FLT
全部
